SynthesisPharmacoEconomics2020
Economic Costs of Myasthenia Gravis: A Systematic Review.
Synthesis in PharmacoEconomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Healthcare costs and burden of myasthenia gravis for patients and society: a systematic review.Journal of neurology · 2026Pooled it
- The Economic Burden of Duchenne Muscular Dystrophy: A Systematic Review.PharmacoEconomics · 2026Pooled it
- Economic burden of myasthenia gravis in France: A nationwide claims database study (STAMINA).The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Myasthenia Gravis (MG) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (MG-REST): Estimating the Clinical and Economic Burden in Ontario, Canada.European journal of neurology · 2026Article
- Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.Journal of managed care & specialty pharmacy · 2026Article
- Perioperative use of eculizumab in patients with thymoma-associated myasthenia gravis: A preliminary case series of five patients.IBRO neuroscience reports · 2026Article
- Disease changes and cost analysis of myasthenia gravis: a 10 years retrospective study from a reference center in Italy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Burden of Disease in Myasthenia Gravis: A Targeted Literature Review.Journal of neurology · 2026Review
- Article
- Health care costs and resource utilization among patients with myasthenia gravis in the United States.Journal of managed care & specialty pharmacy · 2025Article
- Effect of the Administration of Cautionary Drugs on the Risk of Worsening Myasthenia Gravis: A Retrospective Matched Case-Control Study.Yonsei medical journal · 2025Article
- A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity.Frontiers in public health · 2025Article
- Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis.European journal of neurology · 2025Article
- Epidemiology and patient characteristics of the US myasthenia gravis population: real-world evidence from a large insurance claims database.BMJ neurology open · 2025Article
- The burden of disease in seronegative myasthenia gravis: a patient-centered perspective.Frontiers in immunology · 2025Observational
- Myasthenia gravis: understanding treatment patterns and direct medical costs in the Czech Republic.Orphanet journal of rare diseases · 2024Article
- Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) - a register-based study.Journal of neurology · 2024Article
- US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization.Drugs - real world outcomes · 2024Article
- Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.Advances in therapy · 2024Article
- Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population-based registry study.European journal of neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of our study was to conduct a systematic literature review of economic costs (henceforth costs) associated with myasthenia gravis (MG).
methodsWe searched MEDLINE (through PubMed), CINAHL, Embase, PsycINFO, and Web of Science for studies reporting costs of MG published from inception up until March 18, 2020, without language restrictions. Two reviewers independently screened records for eligibility, extracted the data, and assessed included studies for risk of bias using the Newcastle-Ottawa Scale. Costs were inflated and converted to 2018 United States dollars ($).
resultsThe search identified 16 articles for data extraction and synthesis. Estimates of costs of MG were found for samples from eight countries spanning four continents (Europe, North America, South America, and Asia). Across studies, the mean per-patient annual direct medical cost of illness was estimated at between $760 and $28,780, and cost per hospitalization between $2550 and $164,730. The indirect cost of illness was estimated at $80 and $3550. Costs varied considerably by patient characteristics, and drivers of the direct medical cost of illness included intravenous immunoglobulin and plasma exchange, myasthenic crisis, mechanical ventilatory support, and hospitalizations.
conclusionsWe show that the current body of literature of costs of MG is sparse, limited to a few geographical settings and resource categories, mostly dated, and subject to non-trivial variability, both within and between countries. Our synthesis will help researchers and decision-makers identify gaps in the local health economic context of MG and inform future cost studies and economic evaluations in this patient population.
Indexed as
Identifiers
32363541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.